DEXCOM INC
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 8, 2024
DXCM$81.07+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Schedule II – Valuation and Qualifying Accounts
DexCom, Inc.
SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
(In millions)
| Twelve Months EndedDecember 31, | |||
|---|---|---|---|
| Allowance for doubtful accounts | 2023 | 2022 | 2021 |
| Beginning Balance | $7.3 | $5.4 | $7.2 |
| Provision for doubtful accounts | 2.0 | 2.4 | (1.4) |
| Write-offs and adjustments | — | (0.5) | (0.5) |
| Recoveries | — | — | 0.1 |
| Ending Balance | $9.3 | $7.3 | $5.4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.